Cannabidiol and Older Adult Cannabis Users

Description

Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.

Conditions

Sleep, Anxiety, Depression, Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.

Rocky Mountain Cannabis Research Center - Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo-Controlled Study

Cannabidiol and Older Adult Cannabis Users

Condition
Sleep
Intervention / Treatment

-

Contacts and Locations

Boulder

University of Colorado at Boulder, Boulder, Colorado, United States, 80309

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 60 years of age
  • * Able to provide informed consent
  • * Must have used a cannabis product at least once with no negative effects
  • * Must not have been regularly using any cannabis products (\<3x/month) in the last 6 months
  • * Female participants must be postmenopausal
  • * Liver function tests (Alanine transaminase (ALT) and
  • * Aspartate transaminase (AST)) must show levels no greater than 2x the upper normal limits for age
  • * Must be currently taking medication/s for pain, sleep, and/or mood
  • * Blood alcohol level \> 0 at screening (to sign consent form)
  • * Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs
  • * Past or current diagnosis, or family history of diagnosis of psychosis
  • * Current use of anti-epileptic medications (e.g. clobazam, sodium valproate)
  • * Current use of medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide).
  • * Current use of antipsychotic medications
  • * Currently undergoing chemotherapy (to prevent drug interactions)

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Boulder,

Study Record Dates

2028-08-31